Additional OS and PFS Benefits Seen With Aflibercept in Post-Hoc VELOUR Analysis

Patrice Olson
Published: Tuesday, Oct 01, 2013

2013 European Cancer Conference A post-hoc analysis of the VELOUR trial demonstrated additional improvements in both overall survival (OS) and progression-free survival (PFS) in favor of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer (mCRC). The analysis was presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), held September 27 to October 1 in Amsterdam, The Netherlands.

The VELOUR trial of aflibercept plus FOLFIRI versus FOLFIRI plus placebo was designed to include important subgroups of patients with mCRC encountered in the second-line setting, including those who had received prior bevacizumab therapy. VELOUR also included patients who progressed rapidly (<6 months) following adjuvant treatment with oxaliplatin—one of the few phase III trials to do so. The post-hoc analysis of the intent-to-treat (ITT) population excluded these rapid adjuvant progressors. The analysis also found improvements in both OS and PFS regardless of whether or not patients had been exposed to prior bevacizumab therapy.

According to the authors of the post-hoc analysis, rapid adjuvant progressors are usually refractory to any subsequent therapy and have an extremely poor prognosis, thus negatively affecting outcomes regardless of the treatment received. Despite this, an incremental increase in OS of 1.4 months was observed with aflibercept compared with placebo in the overall “all-takers” second-line VELOUR population. A total of 1226 patients were included in the overall VELOUR ITT population.

Of these, 186 in the aflibercept/FOLFIRI arm had received prior bevacizumab as had 187 of the placebo controls. A total of 17 patients in the prior bevacizumab arm were rapid adjuvant progressors, 9 of them having been randomized to aflibercept and the remaining 8 to placebo. Among patients who had not received prior bevacizumab, 426 and 427 had been randomized to aflibercept vs placebo, respectively. Fifty-one patients randomized to aflibercept, and 56 randomized to placebo within the non-bevacizumab subgroup were rapid adjuvant progressors. All rapid adjuvant progressors were excluded from the current post-hoc analysis.

“As expected, when rapid adjuvant progressors were excluded from the overall ITT population, a 1.9-month incremental benefit was observed with aflibercept over placebo…demonstrating a 22.1% relative risk reduction for death,” the authors observe. “These findings reinforce the benefit of aflibercept treatment in clinically relevant populations of mCRC patients, including those with prior bevacizumab use.”

Van Cutsem E, Ferry DR, Lakomy R, et al. Aflibercept/FOLFIRI vs placebo/FOLRIRI in metastatic colorectal cancer: post-hoc analysis of survival by prior bevacizumab use subsequent to exclusion of patients who had recurrence during or within 6 months of completing adjuvant oxaliplatin-based therapy. Presented at: European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract 2260. 

<<< View more from the 2013 European Cancer Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication